Bioiberica will be exhibiting at CPhI Russia 2017, stand 231 from the 28th to the 30th March
- Bioiberica’s Human Health and Heparin Business Units will participate at the CPhl Russia fair, one of the most important events for the pharmaceutical sector
- The Russian pharmaceutical market is positioned at the forefront of pharmaerging markets
The third edition of the CPhI Russia tradeshow, held in Moscow from the 28th to the 30th March, will bring together world leading firms specializing in the manufacture and distribution of active ingredients and finished pharmaceutical products. This year, Bioiberica’s Human Health and Heparin Business Units will present their Pharmaceutical Active Principles (chondroitin sulfate, glucosamine, hyaluronic acid, and heparin) and branded ingredients (Mobilee, b-2Cool, Tendofit and Acti-Joint).
The CPhl Russia fair is a unique opportunity to establish strategic contacts with the leading pharmaceutical firms in Russia. The Russian pharma market is positioned at the forefront of pharmerging markets and is projected to reach a value of US $31.2 billion by 2019.
The Russian Government's ambitious Pharma 2020 plan, introduced in 2009, includes funding of nearly US$5 billion with the aim of dramatically increasing domestic pharmaceutical manufacturing and R&D capabilities.
Related News
On a planet where natural resources are limited and there is increasing concern for the environment, the circular economy has emerged as an innovative and sustainable solution.
We participated in CPHI 2023 in Barcelona, where we showcased our leadership in scientific research, sustainable development and strategic partnerships for a more resilient future with our portfolio of Active Pharmaceutical and Nutraceutical Ingredients.
They've set up Biovall Heparin Science, a joint pharmaceutical innovation project with an investment of 25 million euros and 20 skilled jobs